4.5 Article

Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation

Related references

Note: Only part of the references are listed.
Article Hematology

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse

Esther Onecha et al.

Summary: In cases of treatment failure in acute myeloid leukemia (AML), mutational profiling can help differentiate primary refractoriness from relapse, providing insights for treatment guidance and prognostic risk assessment. Additionally, molecular follow-up using a custom NGS myeloid panel can aid in monitoring treatment response, identifying minimal residual disease markers, guiding post-remission strategies, and selecting new drugs for leukemia relapse.

HAEMATOLOGICA (2021)

Article Oncology

Clonal evolution of acute myeloid leukemia from diagnosis to relapse

Sebastian Vosberg et al.

GENES CHROMOSOMES & CANCER (2019)

Article Hematology

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic. Stem Cell Transplantation

Gita Thanarajasingam et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)

Article Oncology

Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation

Martin Schmidt-Hieber et al.

CANCER GENETICS AND CYTOGENETICS (2010)

Article Biophysics

Cytogenetic evolution patterns in CML post-SCT

K. Karrman et al.

BONE MARROW TRANSPLANTATION (2007)